Table 1.
Baseline demographic, clinical and biochemical characteristics of the subjects
| Total (n = 168) |
Unresolved subclinical hypothyroidism (n = 20) |
Resolved subclinical hypothyroidism (n = 21) |
Euthyroid (n = 127) |
p | |
|---|---|---|---|---|---|
| Age (years) | 64.8 ± 14.6 | 63.8 ± 17.2 | 62.3 ± 19.6 | 65.4 ± 13.7 | 0.639 |
| Male (%) | 88 (52.4) | 8 (40.0) | 11 (52.4) | 69 (54.3) | 0.491 |
| BMI (kg/m2) | 23.9 ± 5.0 | 22.2 ± 7.0 | 23.7 ± 3.3 | 24.2 ± 4.9 | 0.267 |
| SBP (mmHg) | 123.2 ± 13.9 | 119.4 ± 12.6 | 127.5 ± 14.1 | 123.0 ± 14.0 | 0.199 |
| DBP (mmHg) | 76.3 ± 8.2 | 74.4 ± 6.2 | 78.8 ± 9.4 | 76.1 ± 8.3 | 0.255 |
| MAP (mmHg) | 91.9 ± 9.5 | 89.4 ± 7.5 | 95.0 ± 10.6 | 91.7 ± 9.5 | 0.186 |
| Comorbidities | |||||
| Diabetes (%) | 73 (43.5) | 13 (65.0) | 6 (28.6) | 54 (42.5) | 0.057 |
| Coronary artery disease (%) | 30 (17.9) | 4 (20.0) | 7 (33.3) | 19 (15.0) | 0.140 |
| Heart failure (%) | 13 (7.7) | 3 (15.0) | 2 (9.5) | 8 (6.3) | 0.403 |
| Cerebrovascular disease (%) | 29 (17.3) | 4 (20.0) | 4 (19.0) | 21 (16.5) | 0.943 |
| Liver cirrhosis (%) | 7 (4.2) | 1 (5.0) | 0 | 6 (4.7) | 0.674 |
| COPD (%) | 5 (3.0) | 0 | 0 | 5 (3.9) | 0.463 |
| Autoimmune disease (%) | 3 (1.8) | 0 | 0 | 3 (2.4) | 1.00 |
| eGFR (ml/min/1.73 m2) | 41.4 ± 16.1 | 37.9 ± 18.6 | 38.8 ± 14.9 | 42.4 ± 15.9 | 0.370 |
| CKD stage | 0.592 | ||||
| Stage 2 (%) | 21 (12.5) | 2 (10.0) | 1 (4.8) | 18 (14.2) | |
| Stage 3 (%) | 98 (58.3) | 10 (50.0) | 13 (61.9) | 75 (59.1) | |
| Stage 4 (%) | 49 (29.2) | 8 (40.0) | 7 (33.3) | 34 (26.8) | |
| Laboratory data | |||||
| Hemoglobin (g/dL) | 12.0 ± 2.1 | 11.3 ± 0.9 | 11.5 ± 2.3 | 12.1 ± 2.2 | 0.173 |
| Calcium (mg/dL) | 9.0 ± 0.8 | 9.2 ± 1.4 | 8.7 ± 0.9 | 9.0 ± 0.6 | 0.091 |
| Phosphorus (mg/dL) | 3.7 ± 0.9 | 3.9 ± 1.1 | 3.7 ± 0.9 | 3.7 ± 0.8 | 0.467 |
| Total cholesterol (mg/dL) | 178.9 ± 58.2 | 189.9 ± 38.7 | 181.5 ± 106.0 | 176.9 ± 49.8 | 0.661 |
| Triglyceride (mg/dL) | 174.9 ± 113.1 | 179.7 ± 92.6 | 145.9 ± 82.0 | 178.8 ± 119.8 | 0.476 |
| LDL (mg/dL) | 101.8 ± 49.8 | 107.2 ± 38.3 | 111.3 ± 90.8 | 99.6 ± 42.2 | 0.587 |
| Albumin (g/dL) | 3.9 ± 0.7 | 3.7 ± 0.7 | 3.7 ± 0.8 | 4.0 ±0.7 | 0.112 |
| hsCRP (mg/dL)* | 2.5 ± 6.1 | 2.0 ± 4.9 | 2.6 ± 5.8 | 2.6 ± 6.4 | 0.722 |
| Neutrophil to lymphocyte ratio | 3.3 ± 3.2 | 2.8 ± 2.2 | 3.4 ± 3.0 | 2.3 ± 3.3 | 0.713 |
| Medications | |||||
| Number of anti-hypertensive drugs |
2.0 ± 1.3 | 1.9 ± 1.2 | 2.4 ± 1.5 | 1.9 ± 1.3 | 0.354 |
| ACEi or ARB use (%) | 100 (60.6) | 10 (52.6) | 15 (71.4) | 75 (60.0) | 0.459 |
*The results of hsCRP were known in 106 (63.1%) of the 168 patients: 11 in the unresolved subclinical hypothyroid patients, 16 in the resolved subclinical hypothyroid patients and 79 in the euthyroid patients. Abbreviations: BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; MAP, mean arterial pressure; COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular filtration rate; CKD, chronic kidney disease; LDL, low-density lipoprotein cholesterol; ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker.